Litigation Details for American Regent, Inc. v. RK Pharma Inc. (D. Del. 2024)

American Regent, Inc. v. RK Pharma Inc. (D. Del. 2024)

Docket		Date Filed	2024-02-29
Court	District Court, D. Delaware	Date Terminated	2024-04-10
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	11,786,548
Link to Docket	External link to docket

Details for American Regent, Inc. v. RK Pharma Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-02-29				External link to document

American Regent, Inc. v. RK Pharma Inc. (1:24-cv-00268): litigation summary and patent-infringement/ANDA risk analysis

Last updated: July 23, 2026

American Regent, Inc. v. RK Pharma Inc., No. 1:24-cv-00268 (filed 2024), centers on American Regent’s IP asserted against RK Pharma’s proposed generic drug entry. The case posture and outcome turn on whether RK Pharma’s ANDA notice (Paragraph IV or other notice type) targeted Orange Book-listed patents and how the court construes the asserted claims versus RK Pharma’s proposed label and composition/manufacturing evidence.

What is the American Regent v. RK Pharma lawsuit (1:24-cv-00268) about?

Short answer: A Hatch-Waxman patent infringement dispute tied to an FDA generic application by RK Pharma, with American Regent asserting infringement of Orange Book-listed patent(s) covering a branded product and/or its specific claims (composition, method of use, and/or formulation/manufacturing).

What typically is pleaded in American Regent-led ANDA cases

In American Regent versus generic filers, complaints commonly allege:

• RK Pharma filed or submitted an ANDA referencing American Regent’s FDA-approved product.
• RK Pharma’s submission included a certification under 21 U.S.C. § 355(j)(2)(A), (B), (C), or (D), often a § 355(j)(2)(A)(vii) “Paragraph IV” type when patent(s) are still listed in the Orange Book.
• The asserted patents are valid and enforceable.
• RK Pharma’s proposed product and/or use would infringe one or more asserted claims.

What matters for case value

The value drivers in this specific posture are usually:

• Which specific patents were asserted (publication numbers and patent family scope).
• Claim count and claim categories (device/biologic-style method claims versus formulation/composition claims).
• Whether RK Pharma challenges only validity, only non-infringement, or both.
• Whether the case is resolved early by dismissal, consent judgment, or settlement with a stated launch date.

What patent estate and Orange Book listings drive the infringement claims?

Short answer: The litigation’s infringement and validity analysis is driven by the Orange Book patents listed for the reference-listed drug (RLD) and the particular claims American Regent chose to assert.

How to map the asserted patents to likely infringement theories

In American Regent’s generic challenges, infringement theories usually fall into:

• Composition/inactive ingredient and excipient-managed formulation claims
• Active ingredient polymorph/crystal form claims (if applicable)
• Dosage form, particle size, or manufacturing-related claims
• Method-of-use claims if the patent estate includes clinical or dosing instructions

Patent strength depends on claim construction anchors

Litigation outcomes often turn on whether the court finds:

• The asserted claim language is narrowly construed, which can reduce infringement risk
• The generic product does not meet a claim limitation, defeating infringement without requiring full validity analysis
• The patent is anticipated/obvious under cited prior art or lacks enablement/adequate written description

What is the procedural timeline and where is the case right now?

Short answer: The only information available here is the docket identifier (1:24-cv-00268). No filing-stage details, claim lists, court orders, or settlement disclosures are included in the provided input. Without the docket text and filings, no accurate and complete procedural timeline can be produced.

What defenses does RK Pharma typically raise in Paragraph IV ANDA litigation?

Short answer: In Hatch-Waxman Paragraph IV actions, RK Pharma typically raises a mix of invalidity (35 U.S.C. §§ 102/103/112), non-infringement (nonconformance with claim limitations), and procedural defenses tied to ANDA notice content and standing.

Common non-infringement lines

• Proposed formulation differs in ways that avoid a claim limitation.
• Proposed method does not include all steps in the asserted method-of-use claims.
• Manufacturing conditions vary in a way that prevents meeting the claim’s process parameter requirements.

Common validity lines

• Invalidity under obviousness or anticipation using prior art patents, scientific literature, or earlier filings.
• Written description or enablement challenges under 35 U.S.C. § 112.
• Indefiniteness challenges if claim terms lack objective boundaries.

Litigation posture outcomes

Depending on the court’s claim construction and expert record, cases resolve via:

• Summary judgment on infringement or invalidity
• Trial with post-trial appeals
• Early settlement with a stipulated dismissal and licensing/launch schedule

How does ANDA certification affect the scope of infringement in this case?

Short answer: The ANDA certification type determines whether the case includes “safe harbor” analysis (often around product noninfringement during approval process) and which patents are litigated.

Patent-by-patent scope usually follows the certification

If RK Pharma certified non-infringement or invalidity for certain patents, those patents define the infringement and validity scope. If it used a different certification basis (for example, non-expiration basis), the case can be narrower or dismissed as unripe.

What generic entry risks exist for RK Pharma if American Regent prevails?

Short answer: If the court finds infringement of an asserted, still-valid claim, RK Pharma’s ability to launch on the planned date is blocked, which typically triggers either:

• Permanent injunction against FDA approval/launch until patent expiration, or
• A settlement that delays launch and/or licenses.

Typical economic and launch impacts

• Loss of exclusivity from delayed first commercial launch
• Additional “skinny label” redesign risk if the court restricts claim coverage tightly
• Settlement terms often include an agreed launch date tied to a particular patent expiration or a dismissal with covenants

How strong is American Regent’s patent position in this dispute?

Short answer: Strength depends on the specific asserted claims and the cited prior art. No complaint or claim list is included in the provided input; therefore no defensible strength ranking can be generated.

What courts usually find decisive

• Claim limitation specificity: courts often prefer tangible process/formulation limitations over broad functional language.
• Prior art proximity: obviousness wins often require close prior art with predictable results.
• Written description robustness: patents with later filing priority disputes can weaken enablement arguments.
• Federal Circuit claim-construction precedent: reversal risk matters at appeal stage.

What settlements or injunctions are commonly reported in similar American Regent vs. generic cases?

Short answer: These cases often resolve with:

• Dismissal with prejudice after a settlement agreement
• Stipulated injunction scope for specific product configurations
• Licensing or covenant not to sue tied to launch timelines

What to extract from settlement agreements (high-intent checklist)

• Date of dismissal and whether it is with prejudice
• Agreed launch date
• Carve-outs for design changes or new product sizes
• Payment structure (lump sum, milestone payments, or royalties) if disclosed
• Confidentiality terms that restrict patent disclosures

How does this case compare with other Hatch-Waxman disputes involving American Regent?

Short answer: American Regent’s litigation pattern generally targets generic filers that seek ANDA approval for its products with Orange Book patents still listed.

Comparison dimensions that control outcomes

• Number of asserted patents
• Breadth of method vs formulation claims
• Claim survivability after Markman/claim construction
• Whether RK Pharma’s proposed product is a close “line-by-line” match or materially different

Key Takeaways

• American Regent v. RK Pharma (1:24-cv-00268) is an ANDA-driven Hatch-Waxman patent infringement dispute where the Orange Book patent list and the asserted claim set control infringement scope and validity defenses.
• The actionable litigation analysis requires the complaint, asserted patent list, RK Pharma’s ANDA certification type, and the court’s orders. Those documents are not present in the provided input.
• Final risk outcomes typically hinge on claim construction and whether RK Pharma can avoid one or more claim limitations or invalidate asserted claims.

FAQs

1. What does a Paragraph IV ANDA certification mean for litigation scope in cases like American Regent v. RK Pharma?
2. How do courts decide non-infringement in formulation or method-of-use patent disputes tied to ANDAs?
3. What is the typical role of claim construction (Markman) in determining early summary judgment outcomes?
4. What launch dates are usually set in Hatch-Waxman settlements when patents remain listed in the Orange Book?
5. How does the presence of multiple asserted patents change litigation leverage and settlement value?

References

1. American Regent, Inc. v. RK Pharma Inc., No. 1:24-cv-00268 (Docket identifier provided in prompt).